SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 19.05 |
Enterprise Value ($M) | 12.84 |
Book Value ($M) | 21.00 |
Book Value / Share | 3.92 |
Price / Book | 0.91 |
NCAV ($M) | 20.81 |
NCAV / Share | 3.89 |
Price / NCAV | 0.92 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.00 |
Return on Assets (ROA) | 0.00 |
Return on Equity (ROE) | 0.00 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 14.75 |
Current Ratio | 14.75 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 22.32 |
Assets | 22.51 |
Liabilities | 1.51 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 11.20 |
Operating Income | -1.16 |
Net Income | 0.01 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -1.22 |
Cash from Investing | 2.45 |
Cash from Financing | 0.21 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
922 | 5,245 | 17.58 | |
3,949 | 19,137 | 20.64 | |
8,639 | 19,969 | 43.26 | |
(click for more detail) |
Similar Companies | |
---|---|
LGVN – Longeveron Inc. | LIPO – Lipella Pharmaceuticals Inc. |
LIXT – Lixte Biotechnology Holdings, Inc. | LPTX – Leap Therapeutics, Inc. |
LQDA – Liquidia Corporation |